- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06280703
A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)
A Three-Part, Randomized, Double-Blind (Part A) and Open-Label (Part B and Part C), Multi-Dose, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus
The main purpose of this study is to look at the amount of the study drug LY3938577 that gets into the blood stream and how long it takes the body to get rid of it. At a later stage of this study (part B and C) the blood sugar lowering effect and the duration of action of LY3938577 will be evaluated compared to Insulin Degludec.
The study will also evaluate the safety and tolerability of LY3938577 and information about any side effects experienced will be collected.
The study will be conducted in three parts (A, B, and C). Healthy participants in part A will receive one single dose of LY3938577 or a placebo, whereas participants in Parts B and C with T1DM will receive single doses of either LY3938577 or Insulin Deglude given via intravenous (IV) infusion.
The study will last up to approximately 5.5, 10 and 13 weeks for parts A, B, and C, respectively, including screening period.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: This is a single site clinical trial. 1-877-CTLILLY (1-877-285-4559) or
- Phone Number: 1-317-615-4559
- Email: ClinicalTrials.gov@Lilly.com
Study Locations
-
-
Nordrhein-Westfalen
-
Neuss, Nordrhein-Westfalen, Germany, 41460
- Profil Institut für Stoffwechselforschung
-
Principal Investigator:
- Oliver Klein
-
Contact:
- Phone Number: +49 (0) 2131 4018 450
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Part A -
• Participants who are overtly healthy as determined by medical history and physical examination.
Parts B and C -
- Have Type 1 Diabetes Mellitus (T1DM) for at least 2 years with a fasting C-peptide level of 0.20 Nanomoles Per Liter (nmol/L) or less, or nonfasting C-peptide level of 0.30 nmol/L or less at screening.
- Have well-controlled HbA1c between 6.0% to 8.5 percent (%).
- Insulin pump users with a total daily basal dose between 15 to 45 International Unit (IU).
All Parts -
- Have normal blood pressure, pulse rate and safety laboratory test results that are acceptable for the study.
- Have body mass index (BMI) between 18.0 and 35.0 kilograms per meter squared (kg/m²), inclusive, at screening.
- Have venous access sufficient to allow for blood sampling.
- Male and/or female not of childbearing potential.
Exclusion Criteria:
Parts B and C -
- Have had more than 1 emergency room visit or hospitalization due to poor glucose control (hyperglycemia or diabetic ketoacidosis) within the last 6 months prior to screening.
- Have had any episodes of severe hypoglycemia (defined as requiring assistance due to neurologically disabling hypoglycemia) , hypoglycemia unawareness, or both within the last 6 months prior to screening.
- Have been treated with Glucagon-like Peptide-1 Receptor Agonists (GLP1-RA), Dipeptidyl Peptidase 4 (DPP4) inhibitor, Glucose-dependent Insulinotropic Polypeptide (GIP) agonists, Metformin, or Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors within the previous 3 months.
- Have received systemic or inhaled glucocorticoid therapy (excluding topical, intraarticular, and intraocular preparations) for more than 14 consecutive days within 4 weeks before screening.
All Parts -
- Have had any of the following cardiovascular conditions: acute myocardial infarction, New York Heart Association Class III or IV heart failure, or cerebrovascular accident (stroke).
- Have gastroparesis or have undergone gastric bypass (bariatric) surgery or restrictive bariatric surgery (for example, Lap-Band®) prior to screening.
- Have history of renal transplantation, currently receiving renal dialysis, have serum creatinine level of more than 2.00 milligrams per decilitre (mg/dL) or have an estimated glomerular filtration rate of less than 60.0 milliliters (mL) / minute) / 1.73 square meters.
Have acute or chronic hepatitis, or obvious clinical signs or symptoms of any other liver disease except non-alcoholic fatty liver disease (that is, participants with non-alcoholic fatty liver disease are eligible for participation), and/or have elevated liver enzyme measurements, as determined by the local laboratory at screening and as indicated:
- TBL >2 × the Upper Limit of Normal (ULN) in the absence of Gilbert's syndrome, or
- ALT/serum glutamic pyruvic transaminase (SGPT) >2.5 × ULN, or
- AST/serum glutamic oxaloacetic transaminase (SGOT) >2.5 × ULN.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part A: LY3938577
Single dose of LY3938577 administered intravenously (IV) in healthy participants.
|
Administered Intravenously (IV)
|
Placebo Comparator: Part A: Placebo
Single dose of Placebo administered intravenously (IV) in healthy participants.
|
Administered Intravenously (IV)
|
Experimental: Part B: LY3938577
For each euglycemic and hyperglycemic clamps participants with T1DM will receive single doses of LY3938577 administered intravenously (IV) with Insulin Lispro administered at a constant low rate to cover individual participant's basal (fasting) insulin demand to maintain a stable glucose level.
|
Administered Intravenously (IV)
Administered Intravenously (IV)
|
Active Comparator: Part B : Insulin Degludec
For each euglycemic and hyperglycemic clamps participants with T1DM will receive single doses of Insulin Degludec administered intravenously (IV) with Insulin Lispro administered at a constant low rate to cover individual participant's basal (fasting) insulin demand to maintain a stable glucose level.
|
Administered Intravenously (IV)
Administered Intravenously (IV)
|
Experimental: Part C: LY3938577
During 3-step clamp and a hyperglycemic clamp with hypoglycemia provocation participants with T1DM will receive LY3938577 by continuous infusion.
Insulin Lispro will be administered intravenously to maintain a stable glucose level before administration of LY3938577.
|
Administered Intravenously (IV)
Administered Intravenously (IV)
|
Active Comparator: Part C: Insulin Degludec
During 3-step clamp and a hyperglycemic clamp with hypoglycemia provocation participants with T1DM will receive Insulin Degludec by continuous infusion.
Insulin Lispro will be administered intravenously to maintain a stable glucose level before administration of Insulin Degludec.
|
Administered Intravenously (IV)
Administered Intravenously (IV)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part A: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration.
Time Frame: Baseline up to Week 5.5
|
A summary of AEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.
|
Baseline up to Week 5.5
|
Part B: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration.
Time Frame: Baseline up to Week 10
|
A summary of AEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.
|
Baseline up to Week 10
|
Part A: Number of Participants With Clinically Significant Changes in Vital Signs
Time Frame: Baseline up to Week 5.5
|
Baseline up to Week 5.5
|
|
Part B: Number of Participants With Clinically Significant Changes in Vital Signs
Time Frame: Baseline up to Week 10
|
Baseline up to Week 10
|
|
Part A: Number of Participants With Clinically Significant Changes in Safety Laboratory Parameters
Time Frame: Baseline up to Week 5.5
|
Baseline up to Week 5.5
|
|
Part B: Number of Participants With Clinically Significant Changes in Safety Laboratory Parameters
Time Frame: Baseline up to Week 10
|
Baseline up to Week 10
|
|
Part A: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3938577
Time Frame: Predose on day 1 up to day 8 post dose
|
PK: AUC of LY3938577
|
Predose on day 1 up to day 8 post dose
|
Part B: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3938577
Time Frame: Predose on day 1 up to day 14 post dose
|
PK: AUC of LY3938577
|
Predose on day 1 up to day 14 post dose
|
Part A: PK: Maximum Observed Concentration (Cmax) of LY3938577
Time Frame: Predose on day 1 up to day 8 post dose
|
PK: Cmax of LY3938577
|
Predose on day 1 up to day 8 post dose
|
Part B: PK: Maximum Observed Concentration (Cmax) of LY3938577
Time Frame: Predose on day 1 up to day 14 post dose
|
PK: Cmax of LY3938577
|
Predose on day 1 up to day 14 post dose
|
Part C: PK: Concentration of LY3938577
Time Frame: Predose on day 1 up to day 14 post dose
|
Predose on day 1 up to day 14 post dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part B: Pharmacodynamic (PD): Area under the glucose infusion rate curve (GIR AUC) of LY3938577
Time Frame: Predose up to day 14 post dose
|
Measured at different glucose levels in participants with T1DM
|
Predose up to day 14 post dose
|
Part C: PD: Glucose infusion rate (GIR) of LY3938577
Time Frame: Predose up to day 14 post dose
|
Measured at different glucose levels in participants with T1DM
|
Predose up to day 14 post dose
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18792
- J4P-MC-IYAB (Other Identifier: Eli Lilly and Company)
- U1111-1301-8386 (Other Identifier: Universal Trial Number)
- 2023-510365-10-00 (Other Identifier: EU Trial Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on LY3938577
-
Eli Lilly and CompanyRecruitingHealthy | Type 2 Diabetes MellitusUnited States